Alzheimer’s disease (AD) is characterized by extracellular deposits of fibrillar -amyloid (A ) in the brain, a fulminant microglialmediated inflammatory reaction, and neuronal death. The use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) is associated with a reduced risk of AD, which has been attributed to the cholesterol-lowering actions of these drugs. Statins have be...

OBJECTIVE Evidence of a relation between use of lipid lowering drugs and cognitive outcomes is mixed. This study aimed to test the association between use of statins and incidence of dementia and cognitive impairment without dementia (CIND) over 5 years of follow-up. METHODS Data were from a population-based cohort study comprising 1,789 older Mexican Americans. All participants had cognitive...

BACKGROUND AND PURPOSE Previously published meta-analyses exploring the effect of statins on stroke incidence included 20,000 patients and found a 2% to 30% risk reduction. It is not clear whether this is attributable to low-density lipoprotein-cholesterol (LDL-C) reduction. Statin trials have now included >90,000 patients. We have determined the effect of statins and LDL-C reduction on stroke ...

BACKGROUND An emphasis on more aggressive lipid-lowering, particularly of low-density lipoprotein cholesterol, to improve patient outcomes has led to an increased use of combination lipid-lowering drugs. This strategy, while potentially beneficial, has triggered concerns regarding fears of adverse effects, harmful drug interactions, and patient nonadherence. OBJECTIVE To present key data rega...

Hypercholesterolemia and statin use have been unevenly associated with clinical change in Alzheimer's disease dementia. In this longitudinal study, 192 consecutive outpatients with late-onset Alzheimer's disease dementia were stratified according to APOE haplotypes, and followed for one year to investigate associations of lipid profile variations and lipophilic statin therapy with changes in co...

Treatment of hypercholesterolemia with statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) is effective in the primary and secondary prevention of cardiovascular disease. However, statin use is often associated with a variety of muscle-related symptoms or myopathies. Myopathy may be related in part to statin inhibition of the endogenous synthesis of coenzyme Q10, an essential c...

In spite of the unequivocal efficacy of statins in reducing primary and secondary cardiovascular events, the use of these drugs in a considerable number of patients is limited because of statin intolerance, mainly statin-associated muscle symptoms (SAMS). SAMS encompass a broad spectrum of clinical presentations, including mild muscular aching and other types of myalgias, myopathy with the sign...

Objective: the study aimed to analyze prescription of recommended drugs in outpatients with acute coronary syndromes (ACS) at Hanoi Heart Hospital.
 Subjects and methods: Cross-sectional on ACS between 1 January 31 March 2021 Results: The enrolled 154 patients. At discharge, proportion patients 4 was 63.0%. 12 months after using high-intensity statin decreased from 87.7% 42.0%. EF ≤ 40% ha...

Background Expanding statin use may help to alleviate the excess burden of atherosclerotic cardiovascular disease in people living with HIV (PLHIV). Pravastatin and pitavastatin are preferred agents due their lack substantial interaction antiretroviral therapy. We aimed evaluate cost-effectiveness pravastatin for primary prevention among PLHIV United States. Methods developed a microsimulation ...

objective(s):in this study, we aimed at evaluation of electrophysiological and histopathalogical characteristics of statin-induced muscle injury as well as clinical features of patients who develop this condition in terms of frequency and pattern of evolution. materials and methods: forty patients (age 39-74 years) including 25 subjects with type 2 diabetes mellitus, 9 with cardiovascular disea...